BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 20133390)

  • 1. Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.
    Snider NT; Walker VJ; Hollenberg PF
    Pharmacol Rev; 2010 Mar; 62(1):136-54. PubMed ID: 20133390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6.
    Sridar C; Snider NT; Hollenberg PF
    Drug Metab Dispos; 2011 May; 39(5):782-8. PubMed ID: 21289075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cannabinoid system and its pharmacological manipulation--a review, with emphasis upon the uptake and hydrolysis of anandamide.
    Fowler CJ
    Fundam Clin Pharmacol; 2006 Dec; 20(6):549-62. PubMed ID: 17109648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system.
    Cravatt BF; Lichtman AH
    Curr Opin Chem Biol; 2003 Aug; 7(4):469-75. PubMed ID: 12941421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist.
    Snider NT; Nast JA; Tesmer LA; Hollenberg PF
    Mol Pharmacol; 2009 Apr; 75(4):965-72. PubMed ID: 19171674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase.
    Reggio PH; Traore H
    Chem Phys Lipids; 2000 Nov; 108(1-2):15-35. PubMed ID: 11106780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation.
    Schlosburg JE; Kinsey SG; Lichtman AH
    AAPS J; 2009 Mar; 11(1):39-44. PubMed ID: 19184452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endocannabinoid system: physiology and pharmacology.
    Rodríguez de Fonseca F; Del Arco I; Bermudez-Silva FJ; Bilbao A; Cippitelli A; Navarro M
    Alcohol Alcohol; 2005; 40(1):2-14. PubMed ID: 15550444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anandamide: an update.
    Smita K; Sushil Kumar V; Premendran JS
    Fundam Clin Pharmacol; 2007 Feb; 21(1):1-8. PubMed ID: 17227440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.
    Dickason-Chesterfield AK; Kidd SR; Moore SA; Schaus JM; Liu B; Nomikos GG; Felder CC
    Cell Mol Neurobiol; 2006; 26(4-6):407-23. PubMed ID: 16736384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
    De Petrocellis L; Ligresti A; Moriello AS; Allarà M; Bisogno T; Petrosino S; Stott CG; Di Marzo V
    Br J Pharmacol; 2011 Aug; 163(7):1479-94. PubMed ID: 21175579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.
    Gubellini P; Picconi B; Bari M; Battista N; Calabresi P; Centonze D; Bernardi G; Finazzi-Agrò A; Maccarrone M
    J Neurosci; 2002 Aug; 22(16):6900-7. PubMed ID: 12177188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinergic ligands.
    Palmer SL; Thakur GA; Makriyannis A
    Chem Phys Lipids; 2002 Dec; 121(1-2):3-19. PubMed ID: 12505686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
    Kinsey SG; Long JZ; O'Neal ST; Abdullah RA; Poklis JL; Boger DL; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2009 Sep; 330(3):902-10. PubMed ID: 19502530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.
    Castelli MP; Paola Piras A; D'Agostino A; Pibiri F; Perra S; Gessa GL; Maccarrone M; Pistis M
    Eur J Pharmacol; 2007 Nov; 573(1-3):11-9. PubMed ID: 17644084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response.
    De Petrocellis L; Melck D; Bisogno T; Milone A; Di Marzo V
    Neuroscience; 1999; 92(1):377-87. PubMed ID: 10392859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase.
    Pacher P; Bátkai S; Osei-Hyiaman D; Offertáler L; Liu J; Harvey-White J; Brassai A; Járai Z; Cravatt BF; Kunos G
    Am J Physiol Heart Circ Physiol; 2005 Aug; 289(2):H533-41. PubMed ID: 15821037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocannabinoids in the central nervous system--an overview.
    Fride E
    Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):221-33. PubMed ID: 12052038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FAAH and anandamide: is 2-AG really the odd one out?
    Di Marzo V; Maccarrone M
    Trends Pharmacol Sci; 2008 May; 29(5):229-33. PubMed ID: 18394720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoids and the gut: new developments and emerging concepts.
    Izzo AA; Sharkey KA
    Pharmacol Ther; 2010 Apr; 126(1):21-38. PubMed ID: 20117132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.